球囊肺动脉成形术与利奥西呱治疗不可手术慢性血栓栓塞性肺动脉高压的比较:RACE 3期随机对照试验及随访研究
RACE试验在法国23个中心纳入105例初治不可手术CTEPH患者,随机分配至BPA或利奥西呱。随访至第52周两组肺血管阻力下降相似,利奥西呱预处理可减少BPA相关严重不良事件。
要点
- BPA在26周时降低PVR优于利奥西呱,但严重不良事件更多。
- 利奥西呱预处理后BPA相关严重不良事件发生率更低。
- 序贯联合治疗可能为不可手术CTEPH带来获益。
核心结论
- 第26周BPA组肺血管阻力下降幅度大于利奥西呱组,但BPA治疗相关严重不良事件更常见。
- 随访第52周,一线利奥西呱或一线BPA治疗患者的肺血管阻力下降程度相似。
- 利奥西呱预处理患者BPA相关严重不良事件发生率低于一线BPA患者,提示多模式治疗潜在获益。
研究设计与样本
- 3期、多中心、开放标签、平行组随机对照试验,在法国23个肺动脉高压中心进行。
- 纳入105例年龄18-80岁、新诊断不可手术且肺血管阻力>320 dyn·s/cm5的初治CTEPH患者,1:1随机分配至BPA(n=52)或利奥西呱(n=53)。
- 主要终点为第26周肺血管阻力较基线的变化百分比(意向性治疗人群)。
- 完成RACE试验的患者进入额外26周随访研究,症状性且肺血管阻力>320 dyn·s/cm5的患者接受附加治疗。
主要发现
- BPA组治疗相关严重不良事件22/52例(42%),利奥西呱组5/53例(9%)。
- BPA组最常见治疗相关严重不良事件为肺损伤(18/52例,35%),利奥西呱组为严重低血压伴晕厥(2/53例,4%)。
- 无治疗相关死亡。
临床怎么用
- 对于不可手术CTEPH患者,BPA在26周时降低肺血管阻力优于利奥西呱,但需警惕BPA相关严重不良事件。
- 利奥西呱预处理可能降低BPA相关严重不良事件风险,支持序贯联合治疗策略。
- 长期(52周)随访显示一线利奥西呱或一线BPA的肺血管阻力下降程度相似。
局限性
- 开放标签设计可能影响不良事件报告。
- 样本量较小(105例),随访时间有限(52周)。
- 研究仅在法国进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised controlled trials comparing these treatments are lacking. We aimed to evaluate the efficacy and safety of BPA versus riociguat in patients with inoperable CTEPH. METHODS: In this phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension, we enrolled treatment-naive patients aged 18-80 years with newly diagnosed, inoperable CTEPH and pulmonary vascular resistance of more than 320 dyn·s/cm5. Patients were randomly assigned (1:1) to BPA or riociguat via a web-based randomisation system, with block randomisation (block sizes of two or four patients) without stratification. The primary endpoint was change in pulmonary vascular resistance at week 26, expressed as percentage of baseline pulmonary vascular resistance in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of riociguat or had at least one BPA session. Patients who completed the RACE trial continued into an ancillary 26-week follow-up during which symptomatic patients with pulmonary vascular resistance of more than 320 dyn·s/cm5 benefited from add-on riociguat after BPA or add-on BPA after riociguat. This trial is registered at ClinicalTrials.gov, NCT02634203, and is completed. FINDINGS: Between Jan 19, 2016, and Jan 18, 2019, 105 patients were randomly assigned to riociguat (n=53) or BPA (n=52). At week 26, the geometric mean pulmonary vascular resistance decreased to 39·9% (95% CI 36·2-44·0) of baseline pulmonary vascular resistance in the BPA group and 66·7% (60·5-73·5) of baseline pulmonary vascular resistance in the riociguat group (ratio of geometric means 0·60, 95% CI 0·52-0·69; p<0·0001). Treatment-related serious adverse events occurred in 22 (42%) of 52 patients in the BPA group and five (9%) of 53 patients in the riociguat group. The most frequent treatment-related serious adverse events were lung injury (18 [35%] of 52 patients) in the BPA group and severe hypotension with syncope (two [4%] of 53 patients) in the riociguat group. There were no treatment-related deaths. At week 52, a similar reduction in pulmonary vascular resistance was observed in patients treated with first-line riociguat or first-line BPA (ratio of geometric means 0·91, 95% CI 0·79-1·04). The incidence of BPA-related serious adverse events was lower in patients who were pretreated with riociguat (five [14%] of 36 patients vs 22 [42%] of 52 patients). INTERPRETATION: At week 26, pulmonary vascular resistance reduction was more pronounced with BPA than with riociguat, but treatment-related serious adverse events were more common with BPA. The finding of fewer BPA-related serious adverse events among patients who were pretreated with riociguat in the follow-up study compared with those who received BPA as first-line treatment points to the potential benefits of a multimodality approach to treatment in patients with inoperable CTEPH. Further studies are needed to explore the effects of sequential treatment combining one or two medications and BPA in patients with inoperable CTEPH. FUNDING: Programme Hospitalier de Recherche Clinique of the French Ministry of Health and Bayer HealthCare. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022. PMID: 35926542. doi:10.1016/S2213-2600(22)00214-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。